| Q34285231 | A randomized comparison of patients' understanding of number needed to treat and other common risk reduction formats |
| Q43160307 | Abstracts in high profile journals often fail to report harm |
| Q58744182 | Alternative package leaflets improve people's understanding of drug side effects-A randomized controlled exploratory survey |
| Q34278236 | Basic statistics for clinicians: 3. Assessing the effects of treatment: measures of association |
| Q50142263 | Bridging the gap between therapeutic research results and physician prescribing decisions: knowledge transfer, a prerequisite to knowledge translation |
| Q24614627 | CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials |
| Q41496250 | Can facts trump unconditional trust? Evidence-based information halves the influence of physicians' non-evidence-based cancer screening recommendations |
| Q36838989 | Can patient decision aids help people make good decisions about participating in clinical trials? A study protocol |
| Q37101925 | Cancer risk communication in mainstream and ethnic newspapers |
| Q28303682 | Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis |
| Q30614196 | Choice of effect measure for epidemiological data |
| Q36959521 | Clinical implications of numeracy: theory and practice |
| Q38595782 | Common pitfalls in statistical analysis: Absolute risk reduction, relative risk reduction, and number needed to treat |
| Q33790731 | Communicating the risk reduction achieved by cholesterol reducing drugs |
| Q57754041 | Comparaciones abstrusas en los resúmenes de ensayos clínicos en revistas médicas españolas |
| Q41033022 | Competing or complementary? Ethical considerations and the quality of randomized trials |
| Q72676670 | Completeness of reporting trial results: effect on physicians' willingness to prescribe |
| Q42547129 | Conveying the benefits and risks of treatment. |
| Q34560021 | Design features of graphs in health risk communication: a systematic review |
| Q33336223 | Do advertisements for antihypertensive drugs in Australia promote quality prescribing? A cross-sectional study |
| Q30304606 | Does informed consent alter elderly patients' preferences for colorectal cancer screening? Results of a randomized trial |
| Q34963164 | Drugs in the news: an analysis of Canadian newspaper coverage of new prescription drugs. |
| Q41508204 | EUR-ASSESS Project Subgroup Report on Dissemination and Impact |
| Q38619893 | Effectiveness of Helicobacter pylori eradication in the prevention of primary gastric cancer in healthy asymptomatic people: A systematic review and meta-analysis comparing risk ratio with risk difference |
| Q34750495 | Effects of information framing on the intentions of family physicians to prescribe long-term hormone replacement therapy. |
| Q60046656 | Estimating everyday risk: Subjective judgments are related to objective risk, mapping of numerical magnitudes and previous experience |
| Q39755420 | Evaluating Markers for Guiding Treatment |
| Q34752656 | Evaluating randomized trials of screening |
| Q35672166 | Evaluating surrogate endpoints, prognostic markers, and predictive markers: Some simple themes |
| Q34297134 | Evidence based purchasing: understanding results of clinical trials and systematic reviews |
| Q72386075 | Evidence-based care: 2. Setting guidelines: how should we manage this problem? |
| Q28189245 | Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis |
| Q57472139 | Good practices for the design, analysis, and interpretation of observational studies on birth spacing and perinatal health outcomes |
| Q81051159 | Health professionals: how do they assess new medicines? |
| Q35079886 | How a well-grounded minimal important difference can enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure |
| Q36832347 | How can quality of life researchers make their work more useful to health workers and their patients? |
| Q41028733 | How do physicians talk with their patients about risks? |
| Q41957497 | How patient outcomes are reported in drug advertisements |
| Q73800616 | How should therapeutic information be transferred to users? |
| Q83328823 | How to appraise the effectiveness of treatment |
| Q73384781 | Impact of presentation of research results on likelihood of prescribing medications to patients with left ventricular dysfunction |
| Q34733816 | Impact of selective evidence presentation on judgments of health inequality trends: an experimental study |
| Q24804024 | Individualizing therapy - in search of approaches to maximize the benefit of drug treatment (II) |
| Q36887008 | Influence of method of reporting study results on decision of physicians to prescribe drugs to lower cholesterol concentration |
| Q41033009 | Influences on the quality of published drug studies |
| Q58592511 | Interpretation of Time-to-event Outcomes in Randomized Trials: an online randomized experiment |
| Q38578694 | Interpreting and using clinical trials |
| Q34571922 | Meta-analyses of randomised clinical trials in oncology. |
| Q28193955 | Methods of reporting research-results and their influence on decision-making by cardiologists prescribing drugs for primary and secondary prevention |
| Q21144605 | Misrepresentation of randomized controlled trials in press releases and news coverage: a cohort study |
| Q81645391 | Number needed to treat (or harm) |
| Q33651245 | Numbers needed to treat derived from meta-analyses--sometimes informative, usually misleading |
| Q42239674 | Overcoming the knowledge-behavior gap: The effect of evidence-based HPV vaccination leaflets on understanding, intention, and actual vaccination decision |
| Q33942503 | Patient and general practitioner attitudes to taking medication to prevent cardiovascular disease after receiving detailed information on risks and benefits of treatment: a qualitative study. |
| Q77220747 | Portal hypertension and variceal bleeding: an AASLD single topic symposium |
| Q34236426 | Preclusion of pain on injection with propofol: Evaluating the effects of lignocaine or fentanyl pretreatment. |
| Q43778219 | Prescribing propensity: influence of life-expectancy gains and drug costs |
| Q37229335 | Presentation of Benefits and Harms in US Cancer Screening and Prevention Guidelines: Systematic Review |
| Q35132326 | Presentation on websites of possible benefits and harms from screening for breast cancer: cross sectional study |
| Q30579901 | Presenting quantitative information about decision outcomes: a risk communication primer for patient decision aid developers |
| Q33752755 | Prevention and treatment of microvascular and neuropathic complications of diabetes |
| Q51601719 | Prevention of recurrent febrile seizures. |
| Q34712222 | Prevention. How much harm? How much benefit? 1. Influence of reporting methods on perception of benefits. |
| Q42379851 | Preventive therapies: weighing the pros and cons. |
| Q34025127 | Primary prevention of heart disease and stroke: a simplified approach to estimating risk of events and making drug treatment decisions |
| Q36366708 | Progress in clinical neurosciences: measuring the benefit of therapies for neurological disorders. |
| Q42690895 | Promoting healthy skepticism in the news: helping journalists get it right |
| Q51023520 | Putting the public back into public health. Part II. How can public health be accountable to the public? |
| Q26746217 | Randomized controlled trials - a matter of design |
| Q42373261 | Randomized trial of the effect of research design and publication characteristics on physician change |
| Q35225417 | Ratio measures in leading medical journals: structured review of accessibility of underlying absolute risks |
| Q42384245 | Reflections on a month in the life of the Ontario Drug Benefit Plan |
| Q41258764 | Reporting of numerical and statistical differences in abstracts: improving but not optimal |
| Q36404527 | Rethinking health numeracy: a multidisciplinary literature review |
| Q38190876 | Risk as an attribute in discrete choice experiments: a systematic review of the literature. |
| Q33583719 | Risk communication in the patient-health professional relationship |
| Q34055328 | Same information, different decisions: the influence of evidence on the management of hypertension in the elderly |
| Q33759118 | Shifts in mortality curves: saving or extending lives? . |
| Q36957599 | Statistical illiteracy in residents: what they do not learn today will hurt their patients tomorrow |
| Q36727471 | Surrogate endpoint analysis: an exercise in extrapolation |
| Q40799596 | Surveying physicians to determine the minimal important difference: implications for sample-size calculation |
| Q30829459 | Systematic review of topical capsaicin for the treatment of chronic pain |
| Q74620058 | Teaching physicians about different measures of risk reduction may alter their treatment preference |
| Q36856802 | The "number needed to treat" turns 20--and continues to be used and misused |
| Q37117584 | The Drug Facts Box: Improving the communication of prescription drug information |
| Q33778872 | The effects of information framing on the practices of physicians |
| Q58670353 | The ethics of alpha: reflections on statistics, evidence and values in medicine |
| Q33213317 | The exaggerated relations between diet, body weight and mortality: the case for a categorical data approach |
| Q36607279 | The impact of expressions of treatment efficacy and out-of-pocket expenses on patient and physician interest in osteoporosis treatment: implications for pay-for-performance programs. |
| Q42183403 | The number needed to treat: a clinically useful nomogram in its proper context |
| Q38650382 | Time-based measures of treatment effect: reassessment of ticagrelor and clopidogrel from the PLATO trial |
| Q24564452 | Tips for learners of evidence-based medicine: 1. Relative risk reduction, absolute risk reduction and number needed to treat |
| Q37055705 | Understanding and expressing "Risk". |
| Q42595305 | Understanding clinical trials |
| Q24288707 | Understanding of statistical terms routinely used in meta-analyses: an international survey among researchers |
| Q36204788 | Use of relative and absolute effect measures in reporting health inequalities: structured review |
| Q24235966 | Using alternative statistical formats for presenting risks and risk reductions |
| Q59216355 | What do we know about communicating risk? A brief review and suggestion for contextualising serious, but rare, risk, and the example of cox-2 selective and non-selective NSAIDs |
| Q39002727 | What is so odd about odds? |
| Q24524234 | When can odds ratios mislead? Odds ratios should be used only in case-control studies and logistic regression analyses |
| Q44324942 | When risk is low: primary care physicians' counseling about HIV prevention |
| Q42559606 | Who benefits from medical interventions? |
| Q78383271 | [Do clinical trials tell us all the truth? relative versus absolute risks and their influence on the therapeutic decisions of cardiologists] |